Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorFAYE, Moustapha
dc.contributor.authorLEGRAND, Karine
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorLE GALL, Lisa
IDREF: 222223472
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorLEFFONDRE, Karen
dc.contributor.authorOMOROU, Abdou Y
dc.contributor.authorALENCAR DE PINHO, Natalia
hal.structure.identifierBioingénierie tissulaire [BIOTIS]
dc.contributor.authorCOMBE, Christian
dc.contributor.authorFOUQUE, Denis
dc.contributor.authorJACQUELINET, Christian
dc.contributor.authorLAVILLE, Maurice
dc.contributor.authorLIABEUF, Sophie
dc.contributor.authorMASSY, Ziad A
dc.contributor.authorSPEYER, Elodie
dc.contributor.authorPECOITS FILHO, Roberto
dc.contributor.authorSTENGEL, Bénédicte
dc.contributor.authorFRIMAT, Luc
dc.contributor.authorAYAV, Carole
dc.date.accessioned2023-01-16T14:57:12Z
dc.date.available2023-01-16T14:57:12Z
dc.date.issued2022-11-01
dc.identifier.issn1555-905Xen_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/171692
dc.description.abstractEnLate stages of CKD are characterized by significant symptom burden. This study aimed to identify subgroups within the 5-year trajectories of symptom evolution in patients with CKD and to describe associated patient characteristics and outcomes. Among 2787 participants (66% men) with eGFR <60 ml/min per 1.73 m enrolled in the CKD-Renal Epidemiology and Information Network (CKD-REIN) cohort study from July 2013 to May 2016, we assessed symptoms annually using the Kidney Disease Quality of Life-36 (KDQOL-36) questionnaire until December 2020. A total of 9121 measures were reported over follow-up; all participants had symptoms scored for at least one time point. We used a joint latent class-mixed model to distinguish profiles of symptom trajectories. Patient mean age (±SD) at baseline was 67±13 years, and mean eGFR was 33±13 ml/min per 1.73 m. The prevalence of each symptom ranged from 24% (chest pain) to 83% (fatigue), and 98% of participants reported at least one symptom. After a median (interquartile range) follow-up of 5.3 (3.4-6.0) years, 690 participants initiated KRT, and 490 died before KRT. We identified two profiles of symptom trajectories: a "worse symptom score and worsening trajectory" in 31% of participants, characterized by a low initial symptom score that worsened more than ten points over time, and a "better symptom score and stable trajectory" in 69% of participants, characterized by a high initial score that remained stable. Participants in the worse symptom score and worsening trajectory group had more risk factors for CKD progression at baseline, worse quality of life, and a higher risk of KRT and death before KRT than other participants. This study highlights a significant worsening of symptoms in about one third of the participants, whereas the majority reported low symptom severity throughout the study.
dc.language.isoENen_US
dc.subject.enMale
dc.subject.enHumans
dc.subject.enMiddle Aged
dc.subject.enAged
dc.subject.enAged
dc.subject.en80 and over
dc.subject.enFemale
dc.subject.enCohort Studies
dc.subject.enRenal Insufficiency
dc.subject.enChronic
dc.subject.enQuality of Life
dc.subject.enRisk Factors
dc.subject.enSurveys and Questionnaires
dc.title.enFive-Year Symptom Trajectories in Nondialysis-Dependent CKD Patients.
dc.title.alternativeClin J Am Soc Nephrolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.2215/CJN.06140522en_US
dc.subject.halSciences du Vivant [q-bio]en_US
dc.identifier.pubmed36307136en_US
bordeaux.journalClinical Journal of the American Society of Nephrologyen_US
bordeaux.page1588-1597en_US
bordeaux.volume17en_US
bordeaux.hal.laboratoriesBiologie des maladies cardiovasculaires (BMC) - UMR 1034en_US
bordeaux.hal.laboratoriesBioingénierie Tissulaire (BioTis) - U1026
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219
bordeaux.issue11en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionCNRS
bordeaux.institutionCHU de Bordeaux
bordeaux.institutionInstitut Bergonié
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.exportfalse
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Clinical%20Journal%20of%20the%20American%20Society%20of%20Nephrology&amp;rft.date=2022-11-01&amp;rft.volume=17&amp;rft.issue=11&amp;rft.spage=1588-1597&amp;rft.epage=1588-1597&amp;rft.eissn=1555-905X&amp;rft.issn=1555-905X&amp;rft.au=FAYE,%20Moustapha&amp;LEGRAND,%20Karine&amp;LE%20GALL,%20Lisa&amp;LEFFONDRE,%20Karen&amp;OMOROU,%20Abdou%20Y&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée